NIH researchers have identified the cellular mechanics inside brain neurons that explain both why GLP-1 drugs like Ozempic and Wegovy work so powerfully at first and why their appetite-suppressing effects often plateau over time. The discovery opens a path toward next-generation treatments that could sustain weight loss longer and require fewer injections.
The drugs target a specific brain region called the area postrema, which controls appetite. But until now, scientists understood the geography better than the chemistry. What exactly happens inside the neurons when semaglutide reaches them has remained largely a black box.
Using fluorescence imaging to watch semaglutide's effects on living mouse brain tissue, researchers traced the action to a molecular messenger called cAMP. When the drug enters neurons, it triggers increased cAMP levels that suppress hunger signals. The process is not uniform across all cells, however. Some neurons maintained elevated cAMP for extended periods while the drug was present. Others showed only temporary spikes before their response weakened.
"It was not an all or nothing phenomenon," said co-author Michael Krashes of NIH's National Institute of Diabetes and Digestive and Kidney Diseases. "We observed that cAMP responses across cells varied on a continuum."
The reason some neurons lose their response over time lies in how cells manage GLP-1 receptors themselves. Neurons can internalize these receptors or break them down, essentially muting the drug's signal. This cellular adaptation likely explains why weight loss often plateaus weeks or months into treatment with these medications.
The team tested whether they could reverse this fade by adding roflumilast, a drug that blocks PDE4, an enzyme that naturally breaks down cAMP. The compound successfully shifted more neurons toward a sustained response, suggesting a potential strategy for future therapies.
"By digging into these mechanisms, we're beginning to answer some of these questions," said co-author Andrew Lutas of NIDDK, describing the advance as foundational work that eventually could unlock longer-lasting weight loss treatments.
The research carries real implications for patients. If scientists can develop GLP-1 treatments that maintain their cellular effects longer, users could potentially space out injections further apart or achieve weight loss that does not stall at a plateau. But the team emphasizes that animal studies rarely translate directly to humans, and much more investigation is needed.
One significant limitation is that the team could only observe intracellular signals for a few hours. Future studies using advanced imaging techniques aim to track neural responses over days or weeks, revealing whether the patterns seen in this short timeframe hold up over longer periods.
Author Jessica Williams: "This is the kind of granular neurobiology that could genuinely move the needle on why these wonder drugs lose their punch."
Comments